Maxim Seeks Ceplene Development Partner After FDA Request For More Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA indicates that approval of Ceplene for the treatment of acute myeloid leukemia would require confirmatory Phase III trial, Maxim says. The company previously withdrew an NDA for use of the oncologic in advanced malignant melanoma.